Anticipating sales declines, Allergan cuts 460

Reporting a decline in earnings, Allergan announced that it would lay off 5 percent of its staff, or about 460 workers, primarily in the U.S. and Europe. Hardest hit by the cuts will be sales and marketing staff, the company said, as it adjusts to the "reduced short-term sales outlook" for some of its businesses. Release

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.